Central Bank & Trust Co. Has $444,000 Stake in Pfizer Inc. (NYSE:PFE)

Central Bank & Trust Co. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 2.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,729 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. Central Bank & Trust Co.’s holdings in Pfizer were worth $444,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Thrivent Financial for Lutherans boosted its holdings in Pfizer by 2.8% during the second quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company’s stock worth $20,684,000 after buying an additional 20,140 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Pfizer by 7.3% in the 2nd quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company’s stock valued at $23,661,000 after acquiring an additional 57,825 shares during the period. 1832 Asset Management L.P. boosted its stake in Pfizer by 24,961.6% during the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock worth $69,891,000 after acquiring an additional 2,487,919 shares during the last quarter. Fidelis Capital Partners LLC grew its holdings in Pfizer by 1.7% during the second quarter. Fidelis Capital Partners LLC now owns 24,568 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 412 shares during the period. Finally, Gabelli Funds LLC increased its stake in Pfizer by 4.5% in the second quarter. Gabelli Funds LLC now owns 742,113 shares of the biopharmaceutical company’s stock valued at $20,764,000 after purchasing an additional 31,700 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on PFE shares. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim dropped their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.30 on Tuesday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50-day moving average of $26.08 and a 200-day moving average of $27.99.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company earned ($0.17) earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.